Colchicine; An inflammasome inhibitor and a potential therapy in severe COVID19?

Abstract

policy/practice/research/medical education Inflammatory reactions are among the most adverse complications of COVID-19 patients. These reactions occur generally via inflammasomes. Inflammasomes are regulated by some proteins such as NLRP3. Colchicine is well-known drug which bars inflammasome formation by inhibiting NLRP3. In presented article we propose studying efficacy, adverse effects, and exact mechanism of action of colchicine in COVID-19 patients.